Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.

Document Type

Journal Article

Publication Date

6-1-2018

Journal

Steroids

Volume

134

Inclusive Pages

43-52

DOI

10.1016/j.steroids.2018.02.010

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Peer Reviewed

1

Open Access

1

Find in your library

Share

COinS